June 2, 2015 Top News 0 Comments
Roth Capital Reiterates a Buy Rating on Pharming Group
By George Macdonald
In a report released yesterday, Joseph Pantginis from Roth Capital reiterated a Buy rating on Pharming Group (NASDAQ: PHGUF), with a price target of $3. The company’s shares closed last Thursday at $0.37, close to its 52-week low of $0.35.
Pantginis said, “We reiterate our Buy rating and our target of $3. The company’s strategy to expand geographies through collaborations and to develop therapies for rare diseases should bear fruit over the long term, in our opinion. Given the pricing power of orphan drugs and the expanding markets in these indications due to better diagnoses, we believe that Pharming is well-positioned for commercial success.”
The company has a one year high of $0.65 and a one year low of $0.35. Currently, Pharming Group has an average volume of 350.
According to TipRanks, Pantginis is a 5-star analyst with an average return of 8.6% and a 51.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, ImmunoCellular Therapeutics, and Cyclacel Pharmaceuticals.
met dank aan RRR voor het plaatsen op huize erika.